Moleculin Biotech raises ~$8.3M via warrant exercise inducement; issues new Series H warrants for 6.4M shares

Moleculin Biotech, Inc.

Holders exercise 2,122,652 existing warrants at $3.90 per share; gross proceeds ~$8.3M.
Company issues new Series H warrants for up to 6,367,956 shares (300% of exercised) with 5-year term.
New warrant exercise price = lesser of $3.90 or lowest VWAP in 5 trading days post-announcement; floor $0.962.
Shareholder approval required for issuance of new warrant shares; resale registration to be filed by March 31, 2026.
Roth Capital served as financial advisor, receiving 7% of gross proceeds from the warrant exercise.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Moleculin Biotech, Inc. entered into Inducement Letter with holders of certain existing warrants valued at approximately $8.3 million (effective 2026-02-19).

Action: entry
Agreement: equity purchase
Counterparty: holders of certain existing warrants
Value: approximately $8.3 million
Effective: 2026-02-19

Exact text from the filing

On February 19, 2026, Moleculin Biotech, Inc. (the “Company”) entered into warrant exercise inducement offer letters (each, an “Inducement Letter”) with holders of certain existing warrants (the “Holders”) to purchase up to 2,122,652 shares of Company common stock with an exercise price of $3.90 per share (the “Existing Warrants”).

View on SEC.gov

294 material agreements filed in the last 30 days. Browse all material agreements →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-004800

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.